- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02452138
Endotoxin Activity Assay and Microcirculation in Severe Sepsis
17. december 2015 opdateret af: National Taiwan University Hospital
Endotoxin Activity Assay and Microcirculation Examination in Patients With Severe Sepsis
Endotoxin is the major mediator of sepsis resulted from systemic inflammatory response syndrome induced by gram-negative bacteria infection.
The endotoxin related inflammatory response and hypercoagulation can result in microcirculatory dysfunction.
When microcirculatory dysfunction is severe, it can induce multiple organ dysfunction syndrome and death.
This is a prospective observational study, and it will not influence the sepsis treatment decision of the medical care team.
The critically ill severe sepsis patients will be enrolled only if they meet all inclusion criteria, do not meet any exclusion criteria and sign the consent form after explanation of the aim and process of the trial by the primary investigator or research personnel.
After enrollment, the patient will receive serum assay of endotoxin activity (EAA) and endocan level.
The patient will also receive examination of sublingual microcirculation by using the incident dark field video microscope.
After 24 hours, the patient will receive assay of endocan level and examination of sublingual microcirculation.
This study will record the vital signs, laboratory data, dose of vasopressors and inotropic agents, and severity of organ dysfunction.
After 28 days, this study will check the survival, stay of intensive care, stay of hospital, ventilator day, and the results of culture of pathogens.
The patients will be assign to the following three groups by the EAA level: low EAA group (< 0.40 EAA units); intermediate EAA group (0.40-0.59 EAA units); and high EAA group (≧ 0.60 EAA units).
This grouping will be used for statistical analysis and comparison.
The primary goal of this study is to investigate the difference of the prevalence of gram-negative bacteria infection, pathogen, infection source, microcirculation, the severity of disease, and the prognosis among these three groups.
Studieoversigt
Undersøgelsestype
Observationel
Tilmelding (Forventet)
100
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
20 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Patients with severe sepsis
Beskrivelse
Inclusion Criteria:
- patients with the following infections: intraabdominal infection, pneumonia, urinary tract infection, blood stream infection, or wound infection
patients must also meet any one of the following criteria for severe sepsis
- SBP < 90 mm Hg, MAP < 65 mm Hg, or requirement of vasopressors or inotropics
- PaO2/FiO2 < 300
- Creatinine level > 2 mg/dL or increase > 0.5 mg/dL; or urine output < 0.5 mL/kg/h more than 2 hours
- Bilirubin level > 4 mg/dL
- Platelet count < 100 k/uL or decrease more than 50%
- INR > 1.5 or aPTT > 60 sec
- GCS < 13 or 9T
- Lactate > 2 mmol/L (with pH < 7.3 or base excess < -5 mmol/L)
Exclusion Criteria:
- younger than 20 yeras old or greater than 99 years old
- the onset of severe sepsis before enrollment is greater than 24 hours
- pregnant
- have received plymyxin-B hemoperfusion within 24 hours before enrollment
- non-native speaker
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Low EAA
Endotoxin Activity Assay [EAA] level < 0.40 EAA units
|
|
Intermediate EAA
Endotoxin Activity Assay [EAA] level between 0.40-0.59
EAA units
|
|
High EAA
Endotoxin Activity Assay [EAA] level >= 0.60 EAA units
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Difference of the prevalence of gram-negative bacteria infection
Tidsramme: At enrollment
|
Compare the prevalnce of gram-negative bacteria infection among the three groups
|
At enrollment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
28 dages dødelighed
Tidsramme: 28 dage
|
28 dage
|
|
Difference of Total small vessel density
Tidsramme: At Enrollment
|
Total small vessel density will be measured by incident dark field video microscope.
Compare the difference among the three groups.
|
At Enrollment
|
Difference of Perfused small vessel density
Tidsramme: At enrollment
|
Perfused small vessel density will be measured by incident dark field video microscope.
Compare the difference among the three groups.
|
At enrollment
|
Endocan level
Tidsramme: At enrollment
|
Endocan level will be measured by Human Endocan kit.
Compare the difference among the three groups.
|
At enrollment
|
SOFA score
Tidsramme: At enrollement
|
Compare the Sequential Organ Failure Assessment score among the three groups
|
At enrollement
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. januar 2016
Primær færdiggørelse (Forventet)
1. maj 2017
Studieafslutning (Forventet)
1. juni 2017
Datoer for studieregistrering
Først indsendt
20. maj 2015
Først indsendt, der opfyldte QC-kriterier
20. maj 2015
Først opslået (Skøn)
22. maj 2015
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
18. december 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
17. december 2015
Sidst verificeret
1. december 2015
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 201503015RINB
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Sepsis
-
University of Kansas Medical CenterUniversity of KansasRekrutteringSepsis | Septisk chok | Sepsis syndrom | Sepsis, svær | Sepsis bakteriel | Sepsis BakteriæmiForenede Stater
-
Jip GroenInBiomeRekrutteringMikrobiel kolonisering | Neonatal infektion | Neonatal sepsis, tidligt opstået | Mikrobiel sygdom | Klinisk sepsis | Kultur Negativ Neonatal Sepsis | Neonatal sepsis, sent opstået | Kultur Positiv Neonatal SepsisHolland
-
Karolinska InstitutetÖrebro University, SwedenAfsluttetSepsis | Sepsis syndrom | Sepsis, sværSverige
-
The University of QueenslandRoyal Brisbane and Women's HospitalUkendt
-
Ohio State UniversityAfsluttetSepsis, Svær Sepsis og Septisk ShockForenede Stater
-
Indonesia UniversityAfsluttetAlvorlig sepsis med septisk stød | Alvorlig sepsis uden septisk stødIndonesien
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRekrutteringAlvorlig sepsis | Alvorlig sepsis uden septisk stødForenede Stater
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsAfsluttetSepsis | Septisk chok | Alvorlig sepsis | Sepsis syndromDet Forenede Kongerige
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian... og andre samarbejdspartnereAfsluttetSepsis | Septisk chok | Alvorlig sepsis | Infektion | Sepsis syndromForenede Stater
-
Inverness Medical InnovationsAfsluttetSepsis | Systemisk inflammatorisk responssyndrom | Alvorlig sepsis | Sepsis syndromForenede Stater
Kliniske forsøg med Severe sepsis management
-
InflammatixTrukket tilbageLuftvejsinfektioner | Sepsis | Urinvejsinfektioner | Intra-abdominale infektioner | Hud- og bløddelsinfektion | Mistænkt meningitis/encephalitis eller enhver anden infektion
-
Emory UniversityIkke rekrutterer endnu
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.UkendtKritisk lemmeriskæmi | PAD | PAOD - Perifer arteriel okklusiv sygdomKina
-
National Taiwan University Hospital Hsin-Chu BranchUkendtSepsis | Perifer arteriesygdom | Diagnose | Perifer arterieokklusionTaiwan
-
Xinhua Hospital, Shanghai Jiao Tong University...UkendtAkut Respiratory Distress Syndrome (ARDS) | Akut lungeskade (ALI)Kina
-
Xinhua Hospital, Shanghai Jiao Tong University...Afsluttet
-
International AIDS Vaccine InitiativeAfsluttetHIV-infektionerDet Forenede Kongerige, Kenya, Rwanda
-
DascenaUniversity of California, San FranciscoAfsluttetSepsis | Septisk chok | Alvorlig sepsisForenede Stater
-
Boston Children's HospitalRekrutteringSepsisForenede Stater